Theratechnologies’ lead peptide drug conjugate TH1902 receives FDA fast track designation for the treatment of sortilin-expressing cancers

Theratechnologies

4 February 2021 - Theratechnologies is pleased to announce that the United States FDA has granted fast track designation to TH1902 as a single agent for the treatment of patients with sortilin positive recurrent advanced solid tumours that are refractory to standard therapy.

TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. This peptide-drug conjugate is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology.

Read Theratechnologies press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Medicine , US , Fast track